"The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the f"...
Overdosage with carbinoxamine may cause central nervous system depression or stimulation, hallucinations, convulsions, and death. Atropinelike signs and symptoms – dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.
The treatment of overdosage consists of discontinuation of Karbinal ER and institution of symptomatic and supportive therapy. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.
Children Less Than 2 Years Of Age
Karbinal ER is contraindicated in children younger than 2 years of age because deaths have been reported in this age group [see WARNINGS AND PRECAUTIONS].
Karbinal ER is contraindicated in nursing mothers because of the risk of mortality in infants given carbinoxamine-containing products [see Use in Specific Populations].
Karbinal ER is contraindicated in patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Karbinal ER [see WARNINGS AND PRECAUTIONS].
Monoamine Oxidase inhibitors
Last reviewed on RxList: 12/15/2015
Additional Karbinal ER Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.